Pleasanton, California-based Spirometrix, a company working on a breath analysis sensor for early detection and treatment of asthma and COPD, has raised $8.6 million in second round funding. The round was led by NGK Spark Plugs, a Japanese company that manufactures spark plugs and oxygen sensors, which contributed $5 million. Existing investor Simul Investments also contributed. The raise brings the company’s total funding to $12 million.
Spirometrix’s device, which is still under development and not yet FDA-cleared, measures nitric oxide in the breath as a biomarker of asthma and other respiratory diseases. The Fenom sensor system will work similarly to a spirometer — the user will exhale into the device for 10 seconds and get results returned in a minute. But the test has a high sensitivity — it can detect NO in 5 parts per billion.
The sensor device will also include standard sensors like a peak flow meter, GPS, and an environmental sensor for pollen counts. It will be used both as an initial diagnostic test for asthma and to predict episodes in people with existing respiratory conditions. The company says data will be transmitted to patients and physicians via the cloud. Keep reading>>